Brief: Springworks Therapeutics Expects Nirogacestat Decision From European Commission In Q3
20/06/2025 14:45
June 20 (Reuters) - SpringWorks Therapeutics Inc SWTX.O: SPRINGWORKS THERAPEUTICS: NIROGACESTAT DECISION FROM EUROPEAN COMMISSION EXPECTED IN Q3 Source text: ID:nGNEMyQPB Further company coverage: SWTX.O ((( Reuters.Briefs@thomsonreuters.com );))
Recent news on SpringWorks Therapeutics
See all newsBrief: Merck KGaA Completes Acquisition Of Springworks Therapeutics
Brief: Springworks Therapeutics Expects Nirogacestat Decision From European Commission In Q3
Brief: EMA's CHMP Re-Examines Rejection Of Kisunla For Early Alzheimer’S Treatment
Brief: SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
Brief: SpringWorks Therapeutics Receives Positive CHMP Opinion For Mirdametinib For The Treatment Of Adult And Pediatric Patients With NF1-PN